



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Michael Bristow *et al.*

Serial No.: 09/558,472


Filed: April 25, 2000

For: DIAGNOSIS AND TREATMENT OF
MYOCARDIAL FAILURE

Group Art Unit: 1632

Examiner: Thaian N. Ton

Atty. Dkt. No.: MYOG:004USD1

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
May 19, 2004	
Date	Steven L. Highlander

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

This application is a divisional application of Serial No. 09/016,075, filed January 30, 1998, which claims priority to U.S. Provisional Serial No. 60/036,987 filed January 30, 1997 and 60/038,911 filed February 26, 1997 and is relied upon for an earlier filing date under 35 U.S.C. § 120. In accordance with Rule 37 C.F.R. § 1.98(d) only copies of those documents not previously cited and submitted to the Patent and Trademark Office in prior application Serial No. 09/016,075 are enclosed for the convenience of the Examiner

In accordance with 37 C.F.R. § 1.97(e)(1), Applicants hereby certify that each item of information contained in this Supplemental Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the present statement, as evidenced by the date of the enclosed search report.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: May 19, 2004

Form PTO-1449 (modified)

Atty. Docket No.

MYOG:004USD1

Serial No.

09/558,472

List of Patents and Publications for Applicant's

Applicant

Michael Bristow *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

April 25, 2000

Group:

1632

U.S. Patent Documents


See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1



U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B2	WO 93/21339	10/28/93	PCT			English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C61	GenBank Accession Number D00943
	C62	GenBank Accession Number X52889.
	C63	Khouri <i>et al.</i> , "Effects of thyroid hormone on left ventricular performance and regulation of contractile and Ca ²⁺ -cycling proteins in the baboon," <i>Circulation Research</i> , 79(4):727-735, 1996.
	C64	Ladenson <i>et al.</i> , "Reversible alterations in myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism," <i>Proc. Natl. Acad. Sci., USA</i> , 89:5251-5255, 1992.
	C65	Lompre <i>et al.</i> , "Expression of the cardiac ventricular α - and β -myosin heavy chain genes is developmentally and hormonally regulated," <i>J. Biol. Chem.</i> , 259(10):6437-6446, 1984.
	C66	Lowes <i>et al.</i> , "Changes in gene expression in the intact human heart: downregulation of α -myosin heavy chain in hypertrophied failing ventricular myocardium," <i>J. Clin. Invest.</i> , 100(9):2315-2321, 1997.
	C67	Moruzzi <i>et al.</i> , "Medium-term effectiveness of L-thyroxine treatment in idiopathic dilated cardiomyopathy," <i>Am. J. Med.</i> , 101:461-467, 1996.
	C68	Weiss and Leinwand, "The mammalian myosin heavy chain gene family," <i>Annu. Rev. Cell Dev. Biol.</i> , 12:417-439, 1996.

25415383.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.